Oral factor Xa inhibitors are preferred treatments for venous thromboembolism (VTE). While apixaban and rivaroxaban require an initial lead-in period, clinicians may reduce the period if patients have received prior therapeutic parenteral anticoagulation, alth... ...

请注册登录后继续浏览